Trimetazidine in coronary heart disease patients: mechanism of action and controlled trials’ results
Metabolic cardioprotection is an important part of treating patients with coronary heart disease (CHD). The most widely used drug in this group is trimetazidine. Its mechanism of action is based on fatty acids metabolism inhibition, glucose oxidation activation, intracellular ATP deficit prevention....
Main Authors: | , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«SILICEA-POLIGRAF» LLC
2005-04-01
|
Series: | Кардиоваскулярная терапия и профилактика |
Subjects: | |
Online Access: | https://cardiovascular.elpub.ru/jour/article/view/938 |
id |
doaj-aa743dae61be4b2babd77f8dcde5cd19 |
---|---|
record_format |
Article |
spelling |
doaj-aa743dae61be4b2babd77f8dcde5cd192021-07-28T13:50:40Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252005-04-014299107653Trimetazidine in coronary heart disease patients: mechanism of action and controlled trials’ resultsL. V. Kremneva0O. V. Abaturova1S. V. Shalaev2Tumen Cardiology Center, Cardiology Research Institute of Tomsk Scientific Center, Siberian Branch of the Russian Academy of Medical Science, TumenTumen Cardiology Center, Cardiology Research Institute of Tomsk Scientific Center, Siberian Branch of the Russian Academy of Medical Science, TumenTumen Cardiology Center, Cardiology Research Institute of Tomsk Scientific Center, Siberian Branch of the Russian Academy of Medical Science, TumenMetabolic cardioprotection is an important part of treating patients with coronary heart disease (CHD). The most widely used drug in this group is trimetazidine. Its mechanism of action is based on fatty acids metabolism inhibition, glucose oxidation activation, intracellular ATP deficit prevention. Numerous randomized, controlled clinical studies demonstrated trimetazidine antiischemic efficacy, similar to that for beta-adrenoblockers or calcium antagonists. Trimetazidine improves myocardial contractility, reduces clinical manifestations of heart failure. The medication beneficially influences ischemia-associated myocardial dysfunction: stunning, hybernation, preconditioning. Trimetazidine is recommended for treating patients with stable angina and ischemic left ventricular dysfunction, in combination with other drugs. Perspectives of trimetazidine therapy in myocardial revascularization and acute myocardial infarction should be examined in future trials.https://cardiovascular.elpub.ru/jour/article/view/938metabolic cardioprotectiontrimetazidinestable anginamyocardial infarctionheart failuremyocardial revascularization |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
L. V. Kremneva O. V. Abaturova S. V. Shalaev |
spellingShingle |
L. V. Kremneva O. V. Abaturova S. V. Shalaev Trimetazidine in coronary heart disease patients: mechanism of action and controlled trials’ results Кардиоваскулярная терапия и профилактика metabolic cardioprotection trimetazidine stable angina myocardial infarction heart failure myocardial revascularization |
author_facet |
L. V. Kremneva O. V. Abaturova S. V. Shalaev |
author_sort |
L. V. Kremneva |
title |
Trimetazidine in coronary heart disease patients: mechanism of action and controlled trials’ results |
title_short |
Trimetazidine in coronary heart disease patients: mechanism of action and controlled trials’ results |
title_full |
Trimetazidine in coronary heart disease patients: mechanism of action and controlled trials’ results |
title_fullStr |
Trimetazidine in coronary heart disease patients: mechanism of action and controlled trials’ results |
title_full_unstemmed |
Trimetazidine in coronary heart disease patients: mechanism of action and controlled trials’ results |
title_sort |
trimetazidine in coronary heart disease patients: mechanism of action and controlled trials’ results |
publisher |
«SILICEA-POLIGRAF» LLC |
series |
Кардиоваскулярная терапия и профилактика |
issn |
1728-8800 2619-0125 |
publishDate |
2005-04-01 |
description |
Metabolic cardioprotection is an important part of treating patients with coronary heart disease (CHD). The most widely used drug in this group is trimetazidine. Its mechanism of action is based on fatty acids metabolism inhibition, glucose oxidation activation, intracellular ATP deficit prevention. Numerous randomized, controlled clinical studies demonstrated trimetazidine antiischemic efficacy, similar to that for beta-adrenoblockers or calcium antagonists. Trimetazidine improves myocardial contractility, reduces clinical manifestations of heart failure. The medication beneficially influences ischemia-associated myocardial dysfunction: stunning, hybernation, preconditioning. Trimetazidine is recommended for treating patients with stable angina and ischemic left ventricular dysfunction, in combination with other drugs. Perspectives of trimetazidine therapy in myocardial revascularization and acute myocardial infarction should be examined in future trials. |
topic |
metabolic cardioprotection trimetazidine stable angina myocardial infarction heart failure myocardial revascularization |
url |
https://cardiovascular.elpub.ru/jour/article/view/938 |
work_keys_str_mv |
AT lvkremneva trimetazidineincoronaryheartdiseasepatientsmechanismofactionandcontrolledtrialsresults AT ovabaturova trimetazidineincoronaryheartdiseasepatientsmechanismofactionandcontrolledtrialsresults AT svshalaev trimetazidineincoronaryheartdiseasepatientsmechanismofactionandcontrolledtrialsresults |
_version_ |
1721271489154514944 |